Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor‐Tyrosine Kinase Inhibitor Therapies

• Published in: The oncologist (Dayton, Ohio) Vol. 26; no. 6; pp. 476 - 482
• Main Authors: Wiele, Andrew J., Bathala, Tharakeswara K., Hahn, Andrew W., Xiao, Lianchun, Duran, Munevver, Ross, Jeremy A., Jonasch, Eric, Shah, Amishi Y., Campbell, Matthew T., Msaouel, Pavlos, Tannir, Nizar M.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.06.2021; Oxford University Press
• Subjects: Analysis; Antimitotic agents; Antineoplastic agents; Cabozantinib; Carcinoma, Renal cell; Carcinoma, Renal Cell - drug therapy; Care and treatment; Complications and side effects; Diagnosis; Drug therapy; Everolimus - therapeutic use; Genitourinary Cancer; Humans; Immune Checkpoint Inhibitors; Kidney Neoplasms - drug therapy; Lenvatinib; Lenvatinib plus everolimus; Metastasis; Patient outcomes; Pharmaceutical industry; Phenols; Phenylurea Compounds; Protein Kinase Inhibitors - therapeutic use; Quinolines; Receptors, Vascular Endothelial Growth Factor - therapeutic use; Renal cell carcinoma; Retrospective Studies; Tyrosine; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A; United States; Cabozantinib; Immune checkpoint inhibitors; Lenvatinib; Lenvatinib plus everolimus; Renal cell carcinoma

Introduction Lenvatinib (Len) plus everolimus (Eve) is an approved therapy for metastatic renal cell carcinoma (mRCC) after first‐line vascular endothelial growth factor receptor‐tyrosine kinase inhibitors (VEGFR‐TKIs), but limited data exist on the efficacy of Len ± Eve after progression on immune...